Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

once the survival and PFS data are mature. The summary update presented at ASH meeting is available for viewing on the Company's website www.celltherapeutics.com.

About the PIX301 EXTEND trial: PIX301 is the largest and only randomized trial comparing single agent pixantrone to a list of physician's choice of standard chemotherapy to patients with relapsed or refractory aggressive NHL who have failed two or more lines of therapy. There are currently no approved or effective agents for these patients. The successful PIX301 study results formed the basis of the Company's recent MAA submission to the EMA which was validated and accepted for review on November 17th, 2010.

In addition on December 2, 2010 the Company filed a formal appeal with the U.S. Food and Drug Administration (the "FDA") under the FDA's dispute resolution proceedings. The basis for the appeal is based on the Company's belief that the FDA diverged from accepted statistical principles and practices when the FDA applied a more stringent statistical significance level in concluding that the PIX301 primary analysis required an adjustment for type 1 error as if an interim analysis had been conducted. This was not the case in the PIX301 trial where only a single final analysis was undertaken. The Company expects to have a response to the appeal in the first quarter of 2011.

About PIX203 trial design: The PIX203 trial is a first-line randomized phase II study of the CHOP-R versus CPOP-R in high risk and elderly patients with previously untreated DLBCL  The study evaluates replacing doxorubicin in the standard CHOP-R combination regimen with pixantrone as part of the CPOP-R regimen. The objective of the study was to demonstrate non-inferior complete response rates to standard doxorubicin-based therapy while producing significantly less severe acute and chronic cardiac toxicities. The Company plans to submit the results of this study for
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 Vestiage, Inc. (stock ... focused on science-based research and development, sales and ... and nutraceuticals, announced today that it is awarding ... the sale of Reluma Skin Illuminating Facial Care. ... application by sending an email to info(at)vestiageinc(dot)com and ...
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
(Date:5/23/2013)... MD (PRWEB) May 23, 2013 Can ... off from work motivate members of the public to ... researchers including Johns Hopkins Carey Business School ... emphatic yes. Pointing to a large body of recent ... in the May 24, 2013, issue of Science that ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... seven medical,experts in psychiatry from across the world ... action to optimize services for people with a,diagnosis ... bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal author ... Disorders: Clinical,Policy, and Research Challenges which was published ...
... CLAREMONT, Calif., Sept. 18 Keck Graduate Institute,(KGI) ... program for industry,professionals to learn the latest developments ... "Mammalian cell biotechnology has undergone explosive growth over ... George B. and Joy Rathmann,Professor and director of ...
... Life,Sciences, Inc. (Nasdaq: CALP ) today announced ... Conference in New York City, will be webcast ... Kevin Hrusovsky, President,and CEO of Caliper, will be ... webcast can be accessed at, http://events.streamx.us/US/event/eventdetails.aspx?id=ubs20080922 . ...
Cached Biology Technology:Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals 2
(Date:5/22/2013)... 22, 2013. Plastic additives known as phthalates (pronounced ... They turn up in flooring, plastic cups, beach ... Centers for Disease Control and Preventionthe bodies of ... come under increasing scrutiny. A growing collection of ... leech from packaging and mix with food) may ...
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
(Date:5/21/2013)... new analysis shows that the nation,s land and water ... to produce up to 25 billion gallons of algae-based ... the country,s yearly needs. , The findings come from ... be needed to grow significant amounts of algae in ... in the May 7 issue of Environmental Science ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4
... IL, USA, 05. October, 2011 Eurofins MWG ... agreement to combine their expertise in sequencing and ... Integrated Genomics, based in Mount Prospect, Illinois, is ... and services based on the ERGO(tm) genome sequence ...
... Mount Prospect, IL, USA, 05. October, 2011 ... a co-operation agreement to combine their expertise in ... algal organisms. Integrated Genomics, based in Mount Prospect, ... bioinformatics tools and services based on the ERGO ...
... marine reserves to replenish fish stocks has been studied ... communities to thrive remains a mystery. A team of ... of Marine & Atmospheric Science recently tested whether 10 ... on coral communities in Glover,s Reef Marine Reserve, Belize. ...
Cached Biology News: New study of Glover's Reef challenges whether corals will benefit from Marine Reserves' protection 2